Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80. The company’s shares opened today at p1,433. ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

In short, the GSK share price has disappointed shareholders for years. I know, as I have a tiny holding in this business, while my wife has a more meaningful stake. For decades, GSK was my family ...

GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been ...

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

The best Windows laptops run an impressive gamut, from Qualcomm-powered workhorses that refuse to die to dual-display stunners and subtle gaming stations. (Some of them, dare we say, will tempt ...

Teva Pharmaceutical Industries Ltd. ADR-0.93% $19.32B ...

After hours: 7:53:31 p.m. EST ...